Evaluating olutasidenib for patients with specific blood disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the effectiveness of olutasidenib in treating patients with IDH1-mutated clonal cytopenia of undetermined significance (CCUS), lower-risk myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML). The primary objective is to determine the response rate to olutasidenib monotherapy, while secondary objectives include evaluating transfusion independence, safety, survival rates, and the potential for leukemia transformation. Additionally, the study will explore gene expression and DNA methylation profiles to identify predictors of treatment response. Participants will receive olutasidenib and be monitored for various clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

To be considered eligible to participate in this study, a patient must meet ALL inclusion criteria as follows:

1. Pathologically proven CCUS or lower-risk MDS/CMML.

   1. CCUS is defined as the presence of cytopenia (absolute neutrophil count \< 1.8 x 10\^9/L, hemoglobin \< 13 g/dL in males or \< 12 g/dL in females, and/or platelets \< 150 x 10\^9/L) for at least 30 days that are otherwise unexplained and with no diagnostic hematopathologic features of myeloid neoplasms. Patients with known Duffy-null phenotype must have absolute neutrophil counts less than their lower limit of normal.
   2. Lower-risk MDS/CMML includes patients with International Prognostic Scoring System (IPSS) low- or intermediate-1-risk disease and Revised IPSS (IPSS-R) score ≤ 3.5 and Molecular IPSS (IPSS-M) very low-, low-, or moderate low-risk categories.
2. Patients must have a documented IDH1 mutation with variant allele frequency (VAF) ≥ 0.02.
3. Patients ≥ 18 years old.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Appendix A)
5. Acceptable liver function

   1. Bilirubin ≤ 2 times upper limit of normal (ULN) or ≤ 3 times ULN in patients with Gilbert Syndrome.
   2. Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤ 3 times ULN.
6. Acceptable renal function with serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance ≥ 50 mL/min (as assessed by Cockcroft-Gault, Modification of Diet in Renal Disease Formula \[MDRD\], or Chronic Kidney Disease Epidemiology \[CKD-Epi\] validated measures).
7. Negative serum or urine pregnancy test if female of childbearing potential.
8. For fertile men and women, agreement to use highly effective contraceptive methods for the duration of study participation and 90 days after the last dose of study medication. Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide).
9. Agreement for male patients not to donate sperm and for female patients of childbearing potential not to donate ova during the study and for 90 days after the final dose of study drug.
10. Ability and willingness to signed informed consent prior to beginning study and undergoing procedures.

Exclusion Criteria:

To be eligible for entry into the study, the patient must NOT meet any of the exclusion criteria listed below:

1. Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to jeopardize intestinal absorption.
2. Patients with any concurrent uncontrolled clinically significant medical condition, including life-threatening severe infection or psychiatric illness, which could place the patient at unacceptable risk of study treatment.
3. Known active hepatitis B (hepatitis B virus \[HBV\]) or hepatitis C (hepatitis C virus \[HCV\]) or HIV infection.
4. Pregnant or nursing women or women of childbearing potential not using highly effective contraception; male patients not using highly effective contraception as defined in the inclusion criteria.
5. Subject with white blood cell count \> 25 x10\^9/L.

   * Note: hydroxyurea use is permitted to meet this criterion with no washout required.
6. Unwillingness or inability to comply with procedures either required in this protocol or considered standard of care.

Where it's running

• University of Miami
  Miami, Florida, United States Recruiting
• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Kelly Chien, MD — M.D. Anderson Cancer Center
• Study coordinator: Kelly Chien, MD
• Email: kchien@mdanderson.org
• Phone: (713) 745-7584

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Momelotinib plus azacitidine for chronic-phase MDS/MPN and chronic neutrophilic leukemia

  This trial will test whether adding momelotinib to a standard hypomethylating drug helps adults with chronic-phase MDS/MPN or chronic neutrophilic leukemia control their disease and symptoms.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07071155

• Evaluating plasma cytokines in patients with certain blood cancers treated with non-intensive chemotherapy

  This study is trying to see if measuring certain proteins in the blood can help predict how well patients with specific blood cancers do when they receive two different types of chemotherapy.

  Recruiting Nantes University Hospital · Nantes, Loire-Atlantique · NCT06439199

• Using Venetoclax with FLAMSA and Treosulfan for Blood Stem Cell Transplantation in Certain Blood Cancers

  This study is testing if a new combination of medications can make blood stem cell transplants safer and more effective for people with certain serious blood cancers.

  Recruiting at 6 sites Phase 1/2 Heinrich-Heine University, Duesseldorf · Aachen, North Rhine-Westphalia and 5 other locations · NCT05807932

• Assessing the safety and effectiveness of LP-108 with azacitidine for blood cancers

  This study is testing a new combination of LP-108 and azacitidine to see if it helps people with blood cancers like acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia feel better and stay safe during treatment.

  Recruiting at 3 sites Phase 1 Guangzhou Lupeng Pharmaceutical Company LTD. · Nanchang and 2 other locations · NCT05641259

• Combining new treatments for high-risk blood cancers

  This study is testing a new combination of two treatments for people with high-risk blood cancers to see if it is safe and effective in improving their condition.

  Recruiting at 5 sites Phase 1 Clinical Hub for Interventional Research (CHOIR) · Sydney, New South Wales and 4 other locations · NCT05636514

• Using statins to treat patients with clonal cytopenia and myelodysplastic syndromes

  This study is testing whether the cholesterol-lowering drugs atorvastatin and rosuvastatin can help people with clonal cytopenia and lower-risk myelodysplastic syndromes feel better and slow down their disease.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT05483010

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.